Apyx Medical Corporation reaffirmed earnings guidance for the full year ending December 31, 2024. Total revenue in the range of $49.7 million to $52.9 million, representing a decrease of approximately 5% to growth of approximately 1% year-over-year, compared to total revenue of $52.3 million for the year ended December 31, 2023. Net loss attributable to stockholders of approximately $26.5 million to $24.3 million, compared to $18.7 million for the year ended December 31, 2023.
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
1.615 USD | +0.94% | +5.56% | -38.36% |
May. 09 | Transcript : Apyx Medical Corporation, Q1 2024 Earnings Call, May 09, 2024 | |
May. 09 | Stavros Vizirgianakis Enters into Letter Agreement with Apyx Medical | CI |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-38.36% | 55.43M | |
-4.93% | 182B | |
+0.40% | 114B | |
-5.26% | 67.76B | |
+3.63% | 51.91B | |
+7.13% | 43.23B | |
+6.07% | 41.07B | |
+23.27% | 32.07B | |
+15.86% | 25B | |
-2.99% | 24.55B |
- Stock Market
- Equities
- APYX Stock
- News Apyx Medical Corporation
- Apyx Medical Corporation Reaffirms Earnings Guidance for the Full Year Ending December 31, 2024